HCA Healthcare, Inc. (HCA) will report its second quarter 2026 earnings on April 24 after market close. Analysts expect earnings per share of $7.16 and revenue of $19.08 billion. The healthcare giant operates 182 hospitals and numerous outpatient facilities across 20 states and England. With a market cap of $105.4 billion and stock price near $471, investors are watching closely. HCA’s recent earnings history shows a strong beat pattern, raising expectations for another solid performance. Understanding what to watch will help investors prepare for potential market moves.
Earnings Estimates and Historical Performance
Analysts are forecasting solid results for HCA’s Q2 2026 earnings report. The consensus expects $7.16 earnings per share and $19.08 billion in revenue. These estimates reflect steady expectations for the healthcare provider.
Recent Beat Pattern
HCA has demonstrated a strong track record of beating expectations. In the most recent quarter (Q4 2025), the company reported $8.01 EPS versus $7.46 estimated, a beat of 7.4%. Revenue came in at $19.51 billion versus $19.68 billion estimated, a slight miss. The quarter before that (Q3 2025) showed $6.84 EPS versus $6.29 estimated, beating by 8.7%. This pattern suggests management executes well on operations.
Revenue Trend Analysis
Revenue has remained relatively stable over the past four quarters, ranging from $18.3 billion to $19.7 billion. The current estimate of $19.08 billion sits in the middle of this range. This consistency reflects steady patient volumes and pricing power in HCA’s markets. The company’s ability to maintain revenue levels despite healthcare industry pressures is noteworthy.
What Investors Should Watch
Several key metrics will determine whether HCA meets or exceeds expectations on April 24. Investors should focus on operational efficiency, patient volumes, and margin trends.
Operational Efficiency Metrics
Watch for same-hospital revenue growth and patient admission trends. HCA’s strength lies in managing large hospital networks efficiently. Operating margins matter significantly, as the company reported a 15.8% operating margin trailing twelve months. Any expansion or contraction here signals pricing power and cost control. The company’s $54.77 operating cash flow per share demonstrates strong cash generation from core operations.
Debt and Capital Allocation
HCA carries substantial debt with $227.32 interest debt per share. Management’s commentary on debt reduction and capital allocation will be critical. The company’s 5.32x interest coverage ratio shows adequate ability to service debt. Free cash flow of $33.34 per share provides flexibility for dividends and buybacks. Investors should listen for guidance on capital priorities and any changes to shareholder return programs.
Margin Expansion Opportunities
The healthcare sector faces wage pressures and supply chain costs. HCA’s ability to offset these through pricing and operational improvements will be key. Gross margins of 41.5% are healthy, but net margins of 8.97% leave room for improvement. Management commentary on labor costs and pricing power will signal confidence in future profitability.
Analyst Consensus and Market Expectations
Wall Street maintains a decidedly bullish stance on HCA, with strong analyst support and positive sentiment.
Analyst Ratings
The consensus among analysts is overwhelmingly positive. 24 analysts rate HCA as a Buy, while only 6 rate it as Hold and 1 rates it as Sell. This 24-to-1 buy-to-sell ratio reflects confidence in the company’s business model and growth prospects. No analysts rate HCA as a Strong Buy or Strong Sell, suggesting measured optimism rather than extreme positioning.
Valuation Context
HCA trades at a 16.63 price-to-earnings ratio, which is reasonable for a healthcare provider with consistent earnings growth. The 1.39 price-to-sales ratio indicates the market values the company fairly relative to revenue generation. The stock’s 45.2% one-year return shows strong performance, though it’s down 4.5% over the past month, suggesting some recent profit-taking or sector rotation concerns.
Growth Trajectory
Earnings per share growth of 28.5% year-over-year is exceptional for a mature healthcare operator. This growth reflects both operational improvements and share buybacks reducing the share count by 10.8%. Revenue growth of 7.1% is solid for the healthcare sector, indicating market share gains or pricing power.
Meyka AI Grade and Key Takeaways
Meyka AI rates HCA with a grade of B+. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. These grades are not guaranteed and we are not financial advisors.
What the B+ Grade Means
The B+ rating reflects a company with solid fundamentals and positive momentum. HCA scores well on growth metrics and analyst sentiment. However, the grade acknowledges some concerns around leverage and equity metrics. The company’s -1.41 return on equity reflects the impact of share buybacks and debt financing, which reduce book value. This is common in mature healthcare companies but warrants monitoring.
Forecast and Outlook
Meyka’s price forecasts suggest confidence in HCA’s trajectory. The $468.65 yearly forecast is slightly below the current $471.34 price, while the $573.39 three-year forecast implies 21.6% upside. These projections assume continued operational execution and stable healthcare demand. The company’s 3.15x net debt-to-EBITDA ratio is manageable for a healthcare provider, though elevated compared to lower-leverage peers.
Final Thoughts
HCA Healthcare enters its Q2 2026 earnings report with strong momentum and high analyst expectations. The company’s consistent track record of beating EPS estimates, combined with stable revenue generation and exceptional earnings growth, positions it well for another solid quarter. Investors should focus on margin trends, debt management, and forward guidance. With 24 Buy ratings and a Meyka B+ grade, the market remains constructive on HCA’s prospects. The April 24 earnings announcement will likely confirm whether the healthcare provider can sustain its impressive earnings growth trajectory amid ongoing industry challenges.
FAQs
What are analysts expecting from HCA’s Q2 2026 earnings?
Analysts expect HCA to report $7.16 earnings per share and $19.08 billion in revenue, reflecting steady expectations across the company’s hospital and outpatient networks.
Has HCA beaten earnings estimates recently?
Yes. HCA beat EPS estimates in three of the last four quarters, including 8.7% in Q3 2025 and 7.4% in Q4 2025, demonstrating strong operational execution.
What should investors watch during the earnings call?
Monitor same-hospital revenue growth, patient admissions, operating margins, and management commentary on pricing power, labor costs, debt reduction, and capital allocation priorities.
What is the analyst consensus on HCA stock?
Wall Street is bullish: twenty-four Buy ratings, six Hold, and one Sell. This strong consensus reflects confidence in HCA’s business model and growth prospects.
What does Meyka’s B+ grade mean for HCA?
The B+ grade reflects solid fundamentals and positive growth momentum, though it acknowledges concerns around leverage and equity metrics typical in mature healthcare companies.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)